How to access Elevidys from the UAE — the named-patient coordination pathway, 2026

Name: How to access Elevidys from the UAE — the named-patient coordination pathway, 2026 | Reserve Meds
Published: 2026-04-23

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A UAE family of a child with Duchenne muscular dystrophy (DMD) — a progressive, X-linked neuromuscular disorder caused by pathogenic variants in the DMD gene — may receive a recommendation for Elevidys (delandistrogene moxeparvovec-rokl) from their treating paediatric neurologist. Elevidys is FDA-approved as the first AAV-vector-based gene therapy for DMD, developed by Sarepta Therapeutics. Elevidys delivers a micro-dystrophin transgene via a single intravenous infusion. Because it is a one-time gene-therapy infusion requiring a specialised paediatric infusion centre, access typically involves a coordination pathway that may be delivered in-country at a qualified UAE tertiary centre or via international referral.

This guide explains the legal and operational pathway, what your paediatric neurologist needs to coordinate, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Elevidys is a single intravenous infusion of an adeno-associated virus (AAV) vector carrying a shortened dystrophin ("micro-dystrophin") transgene, administered at a qualified paediatric infusion centre. Eligibility is based on genetic confirmation of a pathogenic DMD variant consistent with the FDA-approved indication, weight-based dosing, and absence of contraindicating anti-AAV antibodies (pre-treatment serology is standard). Your paediatric neurologist will confirm diagnosis, check antibody titres, document baseline motor function (North Star Ambulatory Assessment or age-appropriate measure), review cardiac and pulmonary baselines, and plan the peri-infusion immunomodulation protocol. Elevidys carries risks including acute serious liver injury, immune-mediated myositis, and myocarditis; peri-infusion monitoring is intensive.

Is Elevidys legally accessible for UAE patients?

Yes — through the UAE Ministry of Health and Prevention (MoHAP) named-patient coordination framework. Parallel authority operates in Abu Dhabi through the Department of Health (DoH) and in Dubai through the Dubai Health Authority (DHA), depending on where the treating facility is located.

The named-patient mechanism allows a UAE-licensed physician and treatment centre to coordinate administration of a therapy not locally registered when: (a) the therapy has been approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is suitable, (c) the treating physician and infusion centre take clinical responsibility, and (d) the full chain of custody for the product is documented.

Elevidys can, depending on the case, be delivered through a qualified paediatric infusion centre in the UAE (in coordination with the manufacturer's qualified-centre network) or via international referral to a US or European qualified centre. Reserve Meds coordinates either pattern.

How the pathway works, step by step

Consultation with your treating paediatric neurologist. Genetic confirmation of DMD, antibody pre-screening, and a written clinical rationale documenting eligibility and the indicated treatment plan.
Baseline assessment. North Star or age-appropriate motor function, cardiac and pulmonary baselines, liver function, anti-AAV antibody serology, and weight are documented.
MoHAP named-patient / coordination application. Your physician or hospital files the application with clinical rationale, genetic report, antibody results, and the qualified-centre plan.
US-side product sourcing and logistics. Reserve Meds coordinates with our US-licensed specialty wholesale partner and the qualified-centre network to secure Elevidys from authorised distribution with full chain-of-custody.
Cold-chain shipment to the qualified infusion centre. Elevidys requires frozen storage; the product ships with continuous temperature monitoring and chain-of-custody documentation.
Peri-infusion admission, infusion, and monitoring. The child is admitted for the infusion and peri-infusion immunomodulation at the qualified centre, with scheduled follow-up for liver, cardiac, and immune monitoring per FDA labeling.

What documentation your physician needs

Your physician will typically need to provide:

A clinical rationale letter confirming DMD diagnosis, genetic report, functional baseline, and Elevidys as the indicated treatment
Verification of their UAE medical licence
A copy of the DMD genetic diagnostic report
Anti-AAV antibody pre-screening results
Patient identifier (anonymised reference where possible)
Weight-based dosing calculation and the peri-infusion monitoring plan including liver, cardiac, and immune surveillance

Reserve Meds provides a coordination kit that bundles the templates MoHAP reviewers and qualified-centre partners expect to see for paediatric AAV gene-therapy cases.

Costs and timing

Elevidys's US list price for the gene-therapy product sits in an indicative 2026 range of roughly USD 3.0–3.5 million as a one-time infusion. Total cost of care — including pre-infusion workup, antibody screening, peri-infusion admission, the immunomodulation protocol, and extended monitoring — runs higher. International logistics, MoHAP coordination, and concierge case management add incremental cost. If the infusion is delivered in-country at a UAE qualified centre, travel cost is avoided; if delivered via international referral, travel and accommodation for the family are factored in. Reserve Meds issues a full transparent quote at the start of intake.

Indicative timing — not guaranteed — from intake to infusion typically runs 8–16 weeks, driven by antibody screening, MoHAP coordination, cold-chain scheduling, and qualified-centre calendar.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

A culturally-aware note: DMD is a progressive paediatric disease and the window of functional benefit is age- and stage-sensitive. Families often coordinate care across extended networks; our concierge coordination can include parents, grandparents, and extended family in the UAE, GCC, or abroad at the family's designation.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine and gene therapy. For Elevidys specifically, we provide:

Sourcing and qualified-centre liaison. Through our US-licensed specialty wholesale partner operating under DSCSA chain-of-custody, and coordination with the manufacturer's qualified-centre network.
Documentation. Regulatory package for your physician and for MoHAP (or DoH / DHA) review.
Logistics. Cold-chain shipment to the qualified infusion centre, with chain-of-custody.
Concierge case lead. A named point of contact for the family through intake, antibody workup, infusion, and peri-infusion monitoring.

What we do not do: we are not the prescriber, we do not practise medicine, we do not manufacture the gene therapy, and we are not the infusion centre. All clinical decisions remain with your treating paediatric neurologist and the qualified infusion centre. We operate on a waitlist basis during our pre-launch phase.

Frequently asked

Is this legal in the UAE? Yes, when executed through the MoHAP (or DoH/DHA) named-patient framework with appropriate documentation and a qualified paediatric infusion centre. See our trust and compliance page.

Is Elevidys a cure for DMD? Elevidys is a disease-modifying therapy intended to produce micro-dystrophin, not full-length dystrophin. Pivotal study endpoints focused on functional measures. Your paediatric neurologist will discuss realistic outcome expectations and the long-term surveillance plan.

What about the anti-AAV antibody pre-screen? Children with high pre-existing antibody titres against the AAVrh74 vector are not eligible. Pre-screening is a standard first step; your neurologist will order the test.

What are the main safety considerations? Reported risks include acute serious liver injury, immune-mediated myositis, and myocarditis. An intensive peri-infusion monitoring protocol is standard. Your neurology team will explain the full profile.

Will insurance cover this? Cash-pay is the default for international coordination. Some UAE insurers consider rare paediatric gene therapies case by case; we supply documentation for submission but do not process insurance claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026 for paediatric gene-therapy coordination. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Elevidys coordination in the UAE.

Add me to the Elevidys waitlist

Composite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.